Procaps Gr (NASDAQ:PROC) reported quarterly sales of $110.00 million which missed the analyst consensus estimate of $123.90 million by 11.22 percent.
Neurocrine Biosciences’s Return On Capital Employed Overview
According to Benzinga Pro, during Q2, Neurocrine Biosciences (NASDAQ:NBIX) earned $62.80 million, a 99.37% increase from the preceding quarter. Neurocrine Biosciences also posted a total of $288.90 million in sales, a 22.1% increase since Q1.